. "0902-4441" . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "Posp\u00ED\u0161ilov\u00E1, \u0160\u00E1rka" . "Doubek, Michael" . . "Brychtov\u00E1, Yvona" . . "Abnormalities of the TP53 or ATM, cooperating tumor-suppressor genes, significantly worsen the treatment options for chronic lymphocytic leukemia (CLL) patients. Although the aberrations seem to be mutually exclusive in this leukemia, inactivation of the former gene leads to worse prognosis. We tested the in vitro sensitivity of the CLL samples with heterozygous ATM deletion to fludarabine and combination of fludarabine and rituximab; the responses were compared with the TP53-abnormal and wild-type (wt) cells to delimitate relative significance of ATM deletion. METHODS: In vitro analysis was performed on fifty-nine characterized CLL samples using viability assay WST-1. Western blot and real-time RT-PCR were used to monitor the activation of the ATM/p53 pathway." . . "RIV/65269705:_____/09:#0000279" . "9"^^ . "14"^^ . "European Journal of Haematology" . "lymphocytic leukemia"@en . . . . "Abnormality dvou gen\u016F, p53 nebo ATM, dvou kooperuj\u00EDc\u00EDch tumor-supresorov\u00FDch gen\u016F, prokazatlen\u011B zhor\u0161uj\u00ED mo\u017Enosti l\u00E9\u010Dby u pacient\u016F s chronickou lymfocyt\u00E1rn\u00ED leuk\u00E9mi\u00ED\u00ED (CLL). A\u010Dkoli se tyto aberace zdaj\u00ED b\u00FDt u CLL navz\u00E1jem se vylu\u010Duj\u00EDc\u00EDc\u00ED, inaktivace v\u00FD\u0161e zm\u00EDn\u011Bn\u00FDch gen\u016F vedek hor\u0161\u00ED progn\u00F3ze. Testovali jsme in vitro senzitivitu CLL vzork\u016F s heterozygotn\u00ED delec\u00ED ATM k fludarabinu a combinaci fludarabinu a rituximabu; odezvy byly srovn\u00E1v\u00E1ny s bun\u0148kami s abnormalitami v genu TP53 a S wild-type (wt) bu\u0148kam, abychom vymezili relativn\u00ED v\u00FDznam delece ATM. Metody: Provedli jsme anal\u00FDzu na 59 charakterizovan\u00FDch CLL vzorc\u00EDch pomoc\u00ED WST-1 assay. Pro monitoring aktivace ATM/p53 dr\u00E1hy byla pou\u017Eita metoda western-blottingu a kvantitativni real-time PCR. V\u00FDsledky a z\u00E1v\u011Br: Vzorky a abnormalitami v TP53 genu p\u0159i pou\u017Eit\u00ED klinicky relevantn\u00ED koncentrace fludarabinu vykazovaly v\u00FDrazn\u011B vy\u0161\u0161\u00ED rezistenci ne\u017E ostatn\u00ED CLL vzorky (p = 0,012); skupina vzork\u016F s delec\u00ED ATM nebyla rezistentn\u011Bj\u0161\u00ED ne\u017E wt vzorky."@cs . . . "P(NR8445)" . "\u0160mardov\u00E1, Jana" . "Mayer, Ji\u0159\u00ED" . "RIV/65269705:_____/09:#0000279!RIV09-MZ0-65269705" . . . "335768" . "Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to"@en . "P\u0159\u00EDtomnost heterozygotn\u00ED delece ATM nemus\u00ED b\u00FDt rozhoduj\u00EDc\u00ED v prvotn\u00ED odpov\u011Bdi bun\u011Bk chronick\u00E9 lymfocyt\u00E1rn\u00ED leuk\u00E9mie na fludarabin"@cs . . "Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to" . "Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to" . . . . "82" . . "000262347300007" . . "P\u0159\u00EDtomnost heterozygotn\u00ED delece ATM nemus\u00ED b\u00FDt rozhoduj\u00EDc\u00ED v prvotn\u00ED odpov\u011Bdi bun\u011Bk chronick\u00E9 lymfocyt\u00E1rn\u00ED leuk\u00E9mie na fludarabin"@cs . . "2" . "Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to"@en . "10"^^ . "[E8218F9A0D82]" . "\u010Cejkov\u00E1, So\u0148a" . . "Klabusay, Martin" . . "Trbu\u0161ek, Martin" . "Borsk\u00FD, M." . . "Abnormalities of the TP53 or ATM, cooperating tumor-suppressor genes, significantly worsen the treatment options for chronic lymphocytic leukemia (CLL) patients. Although the aberrations seem to be mutually exclusive in this leukemia, inactivation of the former gene leads to worse prognosis. We tested the in vitro sensitivity of the CLL samples with heterozygous ATM deletion to fludarabine and combination of fludarabine and rituximab; the responses were compared with the TP53-abnormal and wild-type (wt) cells to delimitate relative significance of ATM deletion. METHODS: In vitro analysis was performed on fifty-nine characterized CLL samples using viability assay WST-1. Western blot and real-time RT-PCR were used to monitor the activation of the ATM/p53 pathway."@en .